* in the investigator's opinion, has progressive symptoms with likely imminent (24-48 hours) hospitalization or severe covid-19 illness/symptoms * any medical condition that, in the investigator's or designee's opinion, could adversely impact participant safety or key objectives of the study * has a prior history of long covid * has a clinically documents acute infection other than covid-19 * known or suspected pregnancy, planned pregnancy, a positive pregnancy test at screening or are breastfeeding * has participated, or is participating in a clinical reserach study evaluating covid-19 convalescent plasma, mabs against sars-cov-2, or iv immunoglobulin within 2 months or less than 5 half-lives of the investigational product (whichever is longer) prior to the screening visit

* in the investigator's opinion, has progressive symptoms with likely imminent (24-48 hours) hospitalization or severe covid-19 illness/symptoms * any medical condition that, in the investigator's or designee's opinion, could adversely impact participant safety or key objectives of the study * has a prior history of long covid * has a clinically documents acute infection other than covid-19 * known or suspected pregnancy, planned pregnancy, a positive pregnancy test at screening or are breastfeeding * has participated, or is participating in a clinical reserach study evaluating covid-19 convalescent plasma, mabs against sars-cov-2, or iv immunoglobulin within 2 months or less than 5 half-lives of the investigational product (whichever is longer) prior to the screening visit

in the investigator's opinion, has progressive symptoms with likely imminent (24-48 hours) hospitalization or severe covid-19 illness/symptoms any medical condition that, in the investigator's or designee's opinion, could adversely impact participant safety or key objectives of the study has a prior history of long covid has a clinically documents acute infection other than covid-19 known or suspected pregnancy, planned pregnancy, a positive pregnancy test at screening or are breastfeeding has participated, or is participating in a clinical reserach study evaluating covid-19 convalescent plasma, mabs against sars-cov-2, or iv immunoglobulin within 2 months or less than 5 half-lives of the investigational product (whichever is longer) prior to the screening visit

in the investigator's opinion, has progressive symptoms with likely imminent (24-48 hours) hospitalization or severe covid-19 illness/symptoms any medical condition that, in the investigator's or designee's opinion, could adversely impact participant safety or key objectives of the study has a prior history of long covid has a clinically documents acute infection other than covid-19 known or suspected pregnancy, planned pregnancy, a positive pregnancy test at screening or are breastfeeding has participated, or is participating in a clinical reserach study evaluating covid-19 convalescent plasma, mabs against sars-cov-2, or iv immunoglobulin within 2 months or less than 5 half-lives of the investigational product (whichever is longer) prior to the screening visit

in the investigator's opinion, has progressive symptoms with likely imminent (24-48 hours) hospitalization or severe covid-19 illness/symptoms any medical condition that, in the investigator's or designee's opinion, could adversely impact participant safety or key objectives of the study has a clinically documents acute infection other than covid-19 known or suspected pregnancy, planned pregnancy, a positive pregnancy test at screening or are breastfeeding has participated, or is participating in a clinical reserach study evaluating covid-19 convalescent plasma, mabs against sars-cov-2, or iv immunoglobulin within 2 months or less than 5 half-lives of the investigational product (whichever is longer) prior to the screening visit

in the investigator's opinion, has progressive symptoms with likely imminent (24-48 hours) hospitalization or severe covid-19 illness/symptoms any medical condition that, in the investigator's or designee's opinion, could adversely impact participant safety or key objectives of the study has a clinically documents acute infection other than covid-19 known or suspected pregnancy, planned pregnancy, a positive pregnancy test at screening or are breastfeeding has participated, or is participating in a clinical reserach study evaluating covid-19 convalescent plasma, mabs against sars-cov-2, or iv immunoglobulin within 2 months or less than 5 half-lives of the investigational product (whichever is longer) prior to the screening visit